Ares Genetics selected for NVIDIA and AWS programs to accelerate commercialization of its AI-powered Universal Pathogenome Assay – ARESupaNVIDIA...
Prize awarded by the Vienna Economic Chamber to the most innovative companies in Vienna Ares Genetics´ awarded in the category Life Sciences for...
All formal FDA requests for additional information answeredInteractive review ongoing as review nears completion Amsterdam, the Netherlands...
- Signed IVD partnership for Ares Genetics - Progressed implementation of the Curetis - OpGen business combination with S4 filing - More than...
Amsterdam, the Netherlands, and Holzgerlingen, Germany, October 30, 2019, 10:00 am CET - Curetis N.V. (the "Company" and, together with its...
Blinded evaluation study with leading global IVD player demonstrated diagnostic performance in line with FDA...
- Strategic transaction to combine businesses with OpGen Inc. - Revenues increased by approximately 35% year-on-year - Progressing regulatory...
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses Combined company creates a...
Investment bank supports Curetis in assessment of all strategic and tactical financing options Publication of H1-2019 financials postponed to...
Initial focus on non-diagnostic testing with Next Generation Sequencing (NGS) for infection control, outbreak management and researchFirst...
- Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible...
- AKO MED to exclusively distribute Unyvero A50 portfolio in Serbia, North Macedonia, Bosnia Hercegovina, and Montenegro - Preparing inclusion...
Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, July 25, 2019, 08:00 am CEST - Curetis N.V. (the "Company" and...
- Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.